structure in first source
Also Known As:
3-(3,5-dimethyl-4((3-(3-methyl-5-isoxazolyl)propyl)phenyl)-5-trifluoromethyl)-1,2,4-oxadiazole; Picovir
Networked: 49 relevant articles (7 outcomes, 15 trials/studies)

Relationship Network

Bio-Agent Context: Research Results


1. Liu, Siyu: 3 articles (01/2006 - 03/2002)
2. Hayden, Frederick G: 3 articles (11/2005 - 03/2002)
3. Webster, A D B: 3 articles (01/2005 - 01/2003)
4. Chaudhuri, A: 2 articles (08/2010 - 05/2005)
5. Steiner, I: 2 articles (08/2010 - 05/2005)
6. Sainio, K: 2 articles (08/2010 - 05/2005)
7. Salonen, O: 2 articles (08/2010 - 05/2005)
8. Kennedy, P G E: 2 articles (08/2010 - 05/2005)
9. Budka, H: 2 articles (08/2010 - 05/2005)
10. Koskiniemi, M: 2 articles (08/2010 - 05/2005)

Related Diseases

1. Infection
2. Meningitis
3. Enterovirus Infections
4. Human Influenza (Influenza)
01/01/2012 - "In-Silico screening of Pleconaril and its novel substituted derivatives with Neuraminidase of H1N1 Influenza strain."
01/01/2012 - "Pleconaril variants with F, Cl, Br, CH3, OH and aromatic ring substitutions were shown to be effective alternatives to Oseltamivir as anti influenza drugs."
11/01/2013 - "This review highlights ten "hot topics" in current antiviral research: (i) new nucleoside derivatives (i.e., PSI-352938) showing high potential as a direct antiviral against hepatitis C virus (HCV); (ii) cyclopropavir, which should be further pursued for treatment of human cytomegalovirus (HCMV) infections; (iii) North-methanocarbathymidine (N-MCT), with a N-locked conformation, showing promising activity against both α- and γ-herpesviruses; (iv) CMX001, an orally bioavailable prodrug of cidofovir with broad-spectrum activity against DNA viruses, including polyoma, adeno, herpes, and pox; (v) favipiravir, which is primarily pursued for the treatment of influenza virus infections, but also inhibits the replication of other RNA viruses, particularly (-)RNA viruses such as arena, bunya, and hanta; (vi) newly emerging antiarenaviral compounds which should be more effective (and less toxic) than the ubiquitously used ribavirin; (vii) antipicornavirus agents in clinical development (pleconaril, BTA-798, and V-073); (viii) natural products receiving increased attention as potential antiviral drugs; (ix) antivirals such as U0126 targeted at specific cellular kinase pathways [i.e., mitogen extracellular kinase (MEK)], showing activity against influenza and other viruses; and (x) two structurally unrelated compounds (i.e., LJ-001 and dUY11) with broad-spectrum activity against virtually all enveloped RNA and DNA viruses."
04/01/2002 - "This includes, for the treatment of HIV infections, virus adsorption inhibitors (cosalane derivatives, cyanovirin-N), co-receptor antagonists (TAK-779, AMD3100), viral fusion inhibitors (pentafuside T-20, betulinic acid derivatives), viral uncoating inhibitors (azodicarbonamide), nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs: emtricitabine, amdoxovir, dOTC, d4TMP prodrugs, tenofovir disoproxil fumarate), non-nucleoside reverse transcriptase inhibitors (NNRTIs: thiocarboxanilide UC-781, capravirine, SJ-3366, DPC 083, TMC 125/R165335), integrase inhibitors (diketo acids), transcription inhibitors (temacrazine, flavopiridol), protease inhibitors (atazanavir, mozenavir, tipranavir); for the treatment of RSV and paramyxovirus infections, viral fusion inhibitors (R170591, VP-14637, NMS03); for the treatment of picornavirus infections, viral uncoating inhibitors (pleconaril); for the treatment of pesti- (hepaci-, flavi-) virus infections, RNA replicase inhibitors (VP-32947); for the treatment of herpesvirus (HSV, VZV, CMV) infections, DNA polymerase inhibitors (A-5021, L- and D-cyclohexenylguanine); for the treatment of VZV infections, bicyclic furopyrimidine analogues; for the treatment of CMV infections, fomivirsen; for the treatment of DNA virus infections at large (papilloma-, polyoma-, herpes-, adeno- and poxvirus infections), cidofovir; for the treatment of influenza, neuraminidase inhibitors (zanamivir, oseltamivir, RWJ-270201); for the treatment of HBV infections, adefovir dipivoxil; for the treatment of HBV and HCV infections, N-glycosylation inhibitors (N-nonyl-deoxynojirimycin); and, finally, IMP dehydrogenase inhibitors and S-adenosylhomocysteine hydrolase inhibitors, for the treatment of various virus infections, including hemorrhagic fever virus infections."
5. Encephalitis (Encephalitis, Rasmussen)

Related Drugs and Biologics

1. Oseltamivir (Tamiflu)
2. Foscarnet
3. Ganciclovir (Cytovene)
4. Acyclovir (Aciclovir)
5. hydroxide ion
6. Ribavirin (Virazole)
7. Immunoglobulins (Immunoglobulin)
8. Secretory Immunoglobulin A (SIgA)
9. Ghrelin
10. Fenretinide

Related Therapies and Procedures

1. Stents
2. Aftercare (After-Treatment)